Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DTC Ads: Citizen Petition Pushes For Narrow But Strict Music Ban

Executive Summary

KEI argues a wholesale ban on music during the presentation of risk information in drug ads would be a more clear-cut way for FDA to enforce its existing goals. Others say the ban goes much further than past FDA policy and enforcement.

You may also be interested in...



DTC Trouble: ‘Attention-Grabbing Visuals’ Undermine Risk Info, FDA Tells Celgene, Sanofi

US agency is taking a stand against TV ads that present a drug’s serious risks as people are dancing to music or engaging in other compelling activities.

DTC Proposed Rule Leaves Room For Creativity In Meeting Standards

Agency says it will be flexible in assessing if risk information in consumer-focused ads are "clear, conspicuous and neutral," but proposed rule also seeks comment on whether such information should be presented simultaneously in audio and video format.

COVID-19 Vaccine Refresh For Boosters Only? US FDA Position On Primary Series May Have Shifted

FDA advisors will vote 28 June on whether an Omicron component should be included in new COVID-19 booster vaccines. Following WHO recommendations, the FDA may no longer also be looking to update the primary vaccine series at this time. 

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS142664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel